New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
05:40 EDTPSTIPreclinical results for PLX-PAD cells in tendon injury presented at AAOS meeting
Pluristem Therapeutics announced that Dr. Scott Rodeo of New York's Hospital for Special Surgery presented his research findings in a scientific poster titled, "Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury," at the American Academy of Orthopedic Surgeons', or AAOS, Annual Meeting. At the AAOS meeting, Dr. Rodeo's poster presentation concluded that: placental-expanded cell therapy appeared to have an early beneficial effect on tendon healing following collagenase injury in this preclinical model; since these cells are immunoprivileged and are expanded ex vivo, its potential for "off-the-shelf" use is attractive relative to existing cell-based therapies; and additional preclinical studies are necessary to understand how these cells may affect tendon repair.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
05:09 EDTPSTIPluristem moves to large-scale manufacturing after second product line completed
Pluristem Therapeutics announced that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem's proprietary three dimensional cell expansion technology platform. The company's first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension. Pluristem's development plan for the PLX-RAD cells considers numerous potential clinical indications such as: enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency, which can result from immune system disorders, genetic diseases, and treatment of leukemia and other blood cancers; treatment of bone marrow deficiency in patients who have undergone chemotherapy; treatment of acute radiation syndrome, or ARS in conjunction with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases.
October 20, 2014
07:19 EDTPSTIIBC Life Sciences to hold a conference
Subscribe for More Information
October 14, 2014
16:42 EDTPSTIPluristem Therapeutics files $200M mixed securities shelf
October 7, 2014
05:33 EDTPSTIPluristem Therapeutics wins cell therapy patent case in Europe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use